HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RPID
Rapid Micro Biosystems, Inc.
RPID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RPID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
RPID's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RPID PE Valuation
RPID has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RPID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect RPID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RPID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.10 | -$0.09 |
| Q1 2026 | -$1.10 | -$0.07 |
| Q4 2025 | -$1.05 | +$0.03 |
| Q3 2025 | -$1.01 | +$0.11 |
| Q2 2025 | -$1.01 | +$0.16 |
| Q1 2025 | -$1.03 | +$0.18 |
| Q4 2024 | -$1.08 | +$0.14 |
| Q3 2024 | -$1.12 | +$0.23 |
RPID has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RPID on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RPID on profitability, with a higher operating margin.
RPID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.1M | +11% |
| Q1 2026 | $8M | +11% |
| Q4 2025 | $11.3M | +37% |
| Q3 2025 | $7.8M | +3.1% |
| Q2 2025 | $7.3M | +9.7% |
| Q1 2025 | $7.2M | +28% |
| Q4 2024 | $8.2M | +30% |
| Q3 2024 | $7.6M | +24% |
RPID's revenue has grown year over year for 14 quarters in a row: $8M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -153% | +14 points |
| Q1 2026 | -173% | -11 points |
| Q4 2025 | -108% | +16 points |
| Q3 2025 | -145% | +13 points |
| Q2 2025 | -167% | +35 points |
| Q1 2025 | -162% | +93 points |
| Q4 2024 | -124% | +68 points |
| Q3 2024 | -158% | +77 points |
RPID's operating margin was −153% last quarter, up 14 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RPID on cash generation, producing positive trailing cash flow while its opponent burns cash.
RPID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12.5M | -$2.4M |
| Q1 2026 | -$15.5M | -$6.1M |
| Q4 2025 | -$3.3M | +$6.7M |
| Q3 2025 | -$9.1M | -$301K |
| Q2 2025 | -$10.1M | +$512K |
| Q1 2025 | -$9.4M | +$6.7M |
| Q4 2024 | -$10M | -$92K |
| Q3 2024 | -$8.8M | +$1.3M |
RPID has burned cash in almost every quarter: −$40M over the past year, against −$38M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RPID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RPID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.4% | +2.9M shares |
| 1 year | +8.3% | +3.7M shares |
| 3 years | +12% | +5.3M shares |
| 5 years | +52% | +16.6M shares |
RPID has 48M diluted shares, up 8.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RPID Net Leverage
RPID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RPID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.6 | Oversold |
| Stochastic | 4.6 | Oversold |
RPID's weekly RSI is 25 (oversold) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RPID PE vs Healthcare Sector
RPID has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RPID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.81 | 17% below |
| 20 week MA | $1.34 | 50% below |
| 50 week MA | $2.29 | 71% below |
| 100 week MA | $2.57 | 74% below |
| 200 week MA | $1.78 | 62% below |
RPID is in a downtrend: it's below all five of its weekly moving averages, and 62% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over RPID on returns for 2026, with the stronger performance.
RPID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.1 | $11.3 | -53% |
| 2022 | $11.3 | $1.43 | -87% |
| 2023 | $1.43 | $0.74 | -48% |
| 2024 | $0.74 | $0.96 | +30% |
| 2025 | $0.96 | $2.98 | +210% |
| 2026 YTD | $2.98 | $0.67 | -78% |
RPID's yearly returns have swung widely, from +210% in 2025 to −87% in 2022. It's down 78% so far in 2026.